TPO Synergism in Platelet Activation
| Patient No. . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . |
|---|---|---|---|---|---|---|
| . | ADP . | TPO + ADP . | . | TRAP . | TPO + TRAP . | . |
| 1 | 26.8 | 23.3 | 0.87 | 48.6 | 45.4 | 0.93 |
| 2 | 43.9 | 45.3 | 1.03 | 68.5 | 65.6 | 0.96 |
| 3 | 24.9 | 24.0 | 0.96 | 23.9 | 19.9 | 0.83 |
| 4 | 9.8 | 10.9 | 1.11 | 6.8 | 8.6 | 1.26 |
| 5 | 27.3 | 28.7 | 1.05 | 29.6 | 31.4 | 1.06 |
| TAR (mean ± SD; n = 5) | 27 ± 12 | 26 ± 12 | 1.00 ± 0.09 | 36 ± 24 | 34 ± 22 | 1.01 ± 0.16 |
| Healthy control (mean ± SD; n = 10) | 25 ± 11 | 38 ± 10 | 1.61 ± 0.28 | 39 ± 25 | 50 ± 28 | 1.43 ± 0.33 |
| Patient No. . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . |
|---|---|---|---|---|---|---|
| . | ADP . | TPO + ADP . | . | TRAP . | TPO + TRAP . | . |
| 1 | 26.8 | 23.3 | 0.87 | 48.6 | 45.4 | 0.93 |
| 2 | 43.9 | 45.3 | 1.03 | 68.5 | 65.6 | 0.96 |
| 3 | 24.9 | 24.0 | 0.96 | 23.9 | 19.9 | 0.83 |
| 4 | 9.8 | 10.9 | 1.11 | 6.8 | 8.6 | 1.26 |
| 5 | 27.3 | 28.7 | 1.05 | 29.6 | 31.4 | 1.06 |
| TAR (mean ± SD; n = 5) | 27 ± 12 | 26 ± 12 | 1.00 ± 0.09 | 36 ± 24 | 34 ± 22 | 1.01 ± 0.16 |
| Healthy control (mean ± SD; n = 10) | 25 ± 11 | 38 ± 10 | 1.61 ± 0.28 | 39 ± 25 | 50 ± 28 | 1.43 ± 0.33 |
Platelets of TAR patients and of 10 healthy controls were stimulated with either ADP (50 μmol/L, columns 1-3) or TRAP (5 μmol/L, columns 4-6) with (columns 2 and 5) or without (columns 1 and 4) preincubation with rhTPO (20 ng/mL) and analyzed for CD62P expression by flow cytometry. The percentage of CD62P-positive cells after stimulation with or without rhTPO preincubation, as well as the ratio between these data (columns 3 and 6), are shown. Values are the percentage of CD62P+ cells in all columns except 3 and 6.
Abbreviation: SD, standard deviation.